PD1／PDL1通路及其抗体耐药机制的研究进展#br#

临床肿瘤学杂志 ›› 2018, Vol. 23 ›› Issue (6): 563-568.

PD1／PDL1通路及其抗体耐药机制的研究进展#br#

南京南京医科大学第一附属医院肿瘤科

出版日期:2018-06-30 发布日期:2018-08-29

Research progress of PD1／PDL1 pathway and resistance mechanism of its antibodies#br#
#br#

Department of Oncology，the First Affiliated Hospital of Nanjing Medical University

Online:2018-06-30 Published:2018-08-29

摘要/Abstract

摘要： 程序性死亡受体1（PD1）／程序性死亡受体配体1（PDL1）能通过调节细胞信号通路和表观遗传修饰来抑制T细胞、B细胞的增殖和效应作用。近几年来，在多种恶性肿瘤中，PD1／PDL1通路的免疫检查点抑制剂取得了令人惊喜的临床治疗效果，但随之而来的原发性和继发性耐药成为了新的问题，不仅影响了PD1／PDL1抗体的治疗效果，也限制了其在临床的广泛应用。本文就PD1/PDL1相关信号通路以及导致PD1/PDL1抗体耐药的相关机制作一综述。

关键词: 程序性死亡受体1／程序性死亡受体配体1（PD1／PDL1）, 耐药, 表观遗传, 肿瘤微环境

Abstract: Programmed death 1 （PD1） and its ligand （PDL1） can inhibit the proliferation and function of T and B cells by regulating cellular signaling pathways and epigenetic modifications. In the past decade， immune checkpoint blockades， such as inhibitors against PD1／PDL1，have received surprising clinical response in a variety of malignant tumors. However， the subsequent primary and acquired resistance has become a new problem， which not only influences longlasting response of PD1／PDL1 blockade therapy， but also limits its wide application in clinic. This paper will make a review on the related mechanisms of the regulation of PD1／PDL1 pathway and the resistance to PD1／PDL1 blockade therapy.

Key words: Programmed cell death 1／programmed cell death 1 ligand 1（PD1／PDL1）, Drug resistance, Epigenetic modifications, Tumor microenvironment

韩笑, 林沛楠, 王标, 顾艳宏. PD1／PDL1通路及其抗体耐药机制的研究进展#br#[J]. 临床肿瘤学杂志, 2018, 23(6): 563-568.

HAN Xiao, LIN Peinan, WANG Biao, GU Yanhong. Research progress of PD1／PDL1 pathway and resistance mechanism of its antibodies#br#

#br#

[J]. Chinese Clinical Oncology, 2018, 23(6): 563-568.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed